Storia in 3 fonti

Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M

Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer opens London peptide center; Xencor wins $105M from Alexion.

Raccontata da

endpoints.news

benzinga.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M

Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer opens London peptide center; Xencor wins $105M from Alexion.

originale

fiercepharma.com1 g fa

Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie

In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmenta | In hopes of…

Leggi questa versione →

Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M

Confronto fonti

Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M

Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie

Timeline cronologica

Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial

Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie